Poloxipan is used in cancer research as a pan-specific polo-like kinase (PLK) inhibitor targeting the C-terminal non-catalytic polo-box domain (PBD); it also inhibits other phosphoamino acid/phosphotyrosine-binding domains, including the forkhead-associated (FHA) domain of CHK2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the SH2 domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase.